Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atherosclerotic cardiovascular disease is a leading cause of mortality in our countries. Clinically, symptoms could be chest pain suggesting stable angina. Atherosclerosis is influenced by cardiovascular risk factors which obesity (Body Mass Index\>30). Obesity is associated with an increase risk of cardiovascular complications.

Lipoprotein(a) is regarded as an independent risk factor for premature cardiovascular disease. Lp(a) is composed of low-density lipoprotein - like particle bound to glycoprotein molecule: apolipoprotein(a). Plasma levels are determinated to more than 90% by genetic factors (no significant influence of statin, weight, lifestyle factor: diet, exercise). Two study with few patients have found that aspirin lowers serum Lp(a) levels. Elevated Lp(a) is a risk factor for recurrent coronary events in obese patient.

Atherosclerosis is associated with imbalance of coagulation. TFPI (tissue factor pathway inhibitor) is the earliest inhibitor of the blood coagulation process, natural direct inhibitor of tissue factor. In-vitro, TFPI activity is inhibited by high Lp(a) .

The aim of this study is to research reverse association between Lp(a) and TFPI activity in obese patient with chest pain like stable angina suggesting atherosclerotic heart disease and effect of aspirin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chronic Inflammatory Activation in Fat Tissue: An Atherogenic Factor in Severe Coronary Artery Disease

NCT00510705

Severe Coronary Artery Disease Obesity Impaired Glucose Tolerance

TERMINATED NA

Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease

NCT00510588

Stable Coronary Artery Disease Obesity Impaired Glucose Tolerance

COMPLETED NA

Optimized Cardioprotection Therapy in Obese Subjects With CAD

NCT04570527

Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) Obesity Adiposis; Heart

UNKNOWN

TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects.

NCT00379704

Obesity

COMPLETED

Impact of Ageing on Adipose, Muscle and Systemic Inflammation

NCT02777138

Inflammation Aging

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

obese men

obese men with chest pain like angina

blood sample

Intervention Type OTHER

blood sample at inclusion and 1 month after inclusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

blood sample at inclusion and 1 month after inclusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major
* Men
* Obese BMI\>30
* No aspirin treatment before inclusion
* Coronary exploration: coronary angiography or tomography coronary angiography
* Chest pain like stable angina

Exclusion Criteria

* Women
* Severe hepatic insufficiency
* Inflammatory disease
* Neoplasia
* Protein S deficiency
* Aspirin treatment 10 days before inclusion
* Oral anticoagulant treatment at inclusion
* Heparin or low molecular weight heparin treatment at inclusion

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No